CG 8900Alternative Names: CV 890
Latest Information Update: 12 Oct 2006
At a glance
- Originator Cell Genesys
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Liver cancer
Most Recent Events
- 12 Oct 2006 Discontinued - Preclinical for Liver cancer in USA (unspecified route)
- 17 Sep 2001 Preclinical development for Liver cancer in USA (Unknown route)